Know Labs Granted Patent for Bio-RFID™ Technology Invention to Disrupt Medical Diagnostics
Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (“Know Labs”) (OTC: KNWN), an emerging leader in non-invasive medical diagnostics, today announced it has been granted a patent on its Bio-RFID™ technology. The issued patent is broad, covering the platform nature of the Bio-RFID™ technology and health related diagnostics employing spectroscopy in the radio/microwave frequency band.
Phil Bosua, Know Labs CEO and inventor of the Bio-RFID™ technology said, “We are extremely pleased and proud to obtain this patent. It is truly an invention which we believe can disrupt and revolutionize non-invasive human biomarker detection and medical diagnostics.” Know Labs’ first focus with its Bio-RFID™ technology is the wearable non-invasive continuous monitoring of blood glucose levels, an important breakthrough for the diabetes community. The Company is making progress engineering the UBAND Continuous Glucose Monitor (CGM) into its market ready form for clinical trials later this year, the results of which will be submitted to the US Food and Drug Administration for approval.
Know Labs engaged Boustead for its $3 million Reg D 506c subordinated convertible note offering to fund FDA clinical trials and new IP development. Know Labs is a patented technology platform for the non-invasive, continuous, real-time monitoring of blood glucose and other biomolecules. Dr. James “Andy” Anderson, Know Labs Chief Medical Officer, and highly regarded leader in diabetes and epidemiology stated, “This is an exciting and extremely significant patent for health care. The Bio-RFID™ technology is performing in the laboratory with increasing accuracy and precision as it continuously monitors blood glucose levels. Non-invasive glucose monitoring for the diabetes and pre-diabetes community is our first focus. Over time we will identify many indicators of disease, leading one day, I believe, to our ability to provide an early warning detection system for some types of cancer, markers of developing diseases, and even viruses and the health conditions that make us vulnerable to pandemics like the one we are facing today.” The patent, issued by the United States Patent and Trademark Office as US Patent No. 10,548,503 B2, is entitled “Health Related Diagnostics Employing Spectroscopy in Radio/Microwave Frequency Band.” This newly issued patent continues the expansion of the Know Labs intellectual property portfolio. The Company continues to have a significant number of patents pending and aggressively works to expand the reach of its Bio-RFID™ and related electromagnetic technology. A copy of the patent may be found at www.uspto.gov.
Learn more about the offering here: https://www.flashfunders.com/knowlabs
This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Clinical trials are in early stages.
About Know Labs, Inc. Know Labs, Inc. (OTC: KNWN) is a technology company that is developing and commercializing a completely new class of clinical non-invasive biosensors potentially capable of detecting and measuring – continuously and in real-time – biomolecules such as blood glucose, hormone levels, medications, and metabolites – to potentially usher in a new era of personal health and personalized medicine. Know labs has foundational IP portfolio of 14 issued and 24 pending patents with an aggressive IP development plan in place. The executive team is comprised of technology inventors, technology/healthcare executives, and product developers responsible for leading Know Labs from a developmental-stage company to commercialization and scale. For more information, please visit www.knowlabs.co.
About Boustead Securities, LLC
Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.
About Sutter Securities Group, Inc.
Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com.
This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.